bluuebunny/crossref_metadata_2025 huggingface dataset:
Understanding the Complexities of Adolescent Bullying: The Interplay between Peer Relationships, Emotion Regulation, and Victimization
Authors: Bäker Neele , Wilke Jessica , Eilts Jule , von Düring Ute
Published: July 2023

Bullying is a major social problem that is receiving increased attention in society and research. The overarching goal of the current study was to identify risk and protective factors of bullying examining direct effects between peer relationship, emotion regulation, and bullying involvement. Therefore, a cross-sectional study was conducted withN=201students (55.7% female) between the ages of 10 and 15 (M=12.86;SD=1.29). Path model analysis revealed that trust had a negative effect on victimization, dysfunctional emotion regulation had a positive effect on perpetration and victimization, alienation had a positive effect on dysfunctional emotion regulation, and victimization and communication had a positive effect on functional emotion regulation. Additionally, dysfunctional emotion regulation strategies mediate the path from alienation to bullying and to victimization. Study results underline the importance of considering the bullying dynamic from a combined perspective of intra- and interindividual factors. The results partially confirmed the hypotheses and contribute to our knowledge about individual and contextual correlates of bullying in adolescents. The present findings suggest that group facilitation with the entire class in team building could be a useful intervention to strengthen peer relationships as well as the relationships between classmates and teachers and students.
Supplementary Data from The HDAC2-SP1 Axis Orchestrates Protumor Macrophage Polarization
Authors: Zheng Xiang , Sarode Poonam , Weigert Andreas , Turkowski Kati , Chelladurai Prakash , Günther Stefan , Kuenne Carsten , Winter Hauke , Stenzinger Albrecht , Reu Simone , Grimminger Friedrich , Stiewe Thorsten , Seeger Werner , Pullamsetti Soni Savai , Savai Rajkumar
Published: July 2023

Supplementary Data with figires_tables
Supplementary Figures from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Authors: Bei Yuncheng , He Jian , Dong Xuhui , Wang Yuxin , Wang Sijie , Guo Wan , Cai Chengjie , Xu Zhiye , Wei Jia , Liu Baorui , Zhang Nan , Shen Pingping
Published: July 2023

Supplementary Figures and legends
Supplemental Materials from Wnt Signaling Stimulates Cooperation between GREB1 and HNF4α to Promote Proliferation in Hepatocellular Carcinoma
Authors: Matsumoto Shinji , Harada Akikazu , Seta Minami , Akita Masayuki , Gon Hidetoshi , Fukumoto Takumi , Kikuchi Akira
Published: July 2023

Supplemental Materials 1-3.
Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Authors: Chachad Dhruv , Patel Lalit R. , Recio Carlos Vera , Pourebrahim Rasoul , Whitley Elizabeth M. , Wang Wenyi , Su Xiaoping , Xu An , Lee Dung-Fang , Lozano Guillermina
Published: July 2023

Gene annotation performed by HOMER of p53 ChIP peaks from p53R248W osteoblasts
Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Authors: Chachad Dhruv , Patel Lalit R. , Recio Carlos Vera , Pourebrahim Rasoul , Whitley Elizabeth M. , Wang Wenyi , Su Xiaoping , Xu An , Lee Dung-Fang , Lozano Guillermina
Published: July 2023

Gene annotation performed by HOMER of p53 ChIP peaks from WT p53 osteoblasts
Figure S4 from Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf-Mutant Melanoma
Authors: Kim Dahihm , An Luye , Moon Jiwon , Maymi Viviana I. , McGurk Alexander I. , Rudd Brian D. , Fowell Deborah J. , White Andrew C.
Published: July 2023

Different resistance phenotypes observed with and without Ccr2+ macrophages.
Dual Recombinase–Based Mouse Models Help Decipher Cancer Biology and Targets for Therapy
Authors: Sket Tina , Falcomatà Chiara , Saur Dieter
Published: July 2023

The advent of next-generation sequencing (NGS) and single-cell profiling technologies has revealed the complex and heterogenous ecosystem of human tumors under steady-state and therapeutic perturbation. Breakthroughs in the development of genetically engineered mouse models (GEMM) of human cancers that are based on the combination of two site-specific recombinase systems [dual-recombinase system (DRS)] offer fundamental new possibilities to elucidate and understand critical drivers of the diverse tumor phenotypes and validate potential targets for therapy. Here, we discuss opportunities DRS-based cancer GEMMs offer to model, trace, manipulate, and functionally investigate established cancers, their interactions with the host, and their response to therapy.
Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).
Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Table S5: GO analysis of the shRNA screen in αEPHA2-Cond cells.
Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
Figure S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Fig. S5. A. Heatmap of the BioID hits that are enriched in the top 15 GO processes based onGSEA software. B. Gene Set Enrichment Analysis plots of the top 15 GO process for the BioIDdata produced by GSEA software used to generate the heatmap in A.
Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Details of diabetes medications.
Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

A) Heat map of the 770 transcripts analyzed with the Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared with non-diabetic controls (n=11). B) Heat map of selected differently transcripted genes.
Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Scatter diagram with regression line summarizing the linear regression analysis between the median baseline glycaemia (used as independent variable: x-axes) and median baseline NLR (used as dependent variable: y-axes). 133 patients included; A significant regression equation was found F(1,131)= 4.09, p = 0.04) with an R2 of .030. NLR: neutrophil to lymphocyte ratio.
Supplementary Figure S1 from The Impact of Germline Alterations in Appendiceal Adenocarcinoma
Authors: Foote Michael B. , Walch Henry , Kemel Yelena , Vakiani Efsevia , Johannet Paul , Sheehan Margaret , Chatila Walid , Chung Sebastian , Nash Garrett M. , Maio Anna , Shia Jinru , Mandelker Diana , Berger Michael , Schultz Nikolaus , Diaz Luis A. , Cercek Andrea , Stadler Zsofia K.
Published: July 2023

Supplemental Figure 1: Appendix cancer specific survival in patients with stage IV appendiceal adenocarcinoma stratified by presence of a germline variant. Highlighted Kaplan Meier curve areas display the 95% confidence interval for the respective survival curves.
Supplementary Table S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Authors: Wang Qiao-Li , Ma Chao , Yuan Chen , Shi Qian , Wolpin Brian M. , Zhang Yin , Fuchs Charles S. , Meyer Jeffrey , Zemla Tyler , Cheng En , Kumthekar Priya , Guthrie Katherine A. , Couture Felix , Kuebler Philip , Kumar Pankaj , Tan Benjamin , Krishnamurthi Smitha , Goldberg Richard M. , Venook Alan , Blanke Charles , Shields Anthony F. , O'Reilly Eileen M. , Meyerhardt Jeffrey A. , Ng Kimmie
Published: July 2023

Table S3. Sensitivity analysis of the association between plasma 25-hydroxyvitamin level and disease-free survival, overall survival, and time to recurrence, excluding patients who recurred or died within three months of blood collection
Supplementary Table S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
Authors: Morgan Robert D. , Clamp Andrew R. , White Daniel J. , Price Marcus , Burghel George J. , Ryder W. David J. , Mahmood Reem D. , Murphy Alexander D. , Hasan Jurjees , Mitchell Claire L. , Salih Zena , Wheeler Chelsey , Buckley Emma , Truelove Joanna , King Georgia , Ainaoui Yasmina , Bhaskar Sanjeev S. , Shaw Joseph , Evans D. Gareth R. , Kilerci Bedirhan , Pearce Simon P. , Brady Gerard , Dive Caroline , O'Connor James P.B. , Wallace Andrew J. , Rothwell Dominic G. , Edmondson Richard J. , Jayson Gordon C.
Published: July 2023

Progression-free survival according to functional homologous recombination repair and somatic copy-number alteration status.
Table S4 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Authors: Rastegar Bahar , Andersson Natalie , Petersson Alexandra , Karlsson Jenny , Chattopadhyay Subhayan , Valind Anders , Jansson Caroline , Durand Geoffroy , Romerius Patrik , Jirström Karin , Holmquist Mengelbier Linda , Gisselsson David
Published: July 2023

Supplementary Table 4. Segmental aberrations. All 20 Wilms tumor (WT) cases and their corresponding samples are listed. ‘Sample position’ refers to the individual sample and its position in a certain paraffin block (see Figure 1 for details.) For each genetic event the following information is given: the ploidy level (Ploidy), chromosome (chr), the genomic start and end positions, genetic events annotated as gain, loss, CNNI (copy neutral imbalance) or homozygous loss, the length of the aberration (bp), which chromosomal cytoband, the median log2 ratio, allelic composition and mutated cell fraction (MCF). IR= intermediate risk, BT= blastemal type, DA= diffuse anaplasia. Genomic positions accordning to hg19.
Figure S1 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Authors: Rastegar Bahar , Andersson Natalie , Petersson Alexandra , Karlsson Jenny , Chattopadhyay Subhayan , Valind Anders , Jansson Caroline , Durand Geoffroy , Romerius Patrik , Jirström Karin , Holmquist Mengelbier Linda , Gisselsson David
Published: July 2023

Supplementary Figure 1 Geographic overview of histological and genetic features.
Fig S2 from Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution
Authors: Rastegar Bahar , Andersson Natalie , Petersson Alexandra , Karlsson Jenny , Chattopadhyay Subhayan , Valind Anders , Jansson Caroline , Durand Geoffroy , Romerius Patrik , Jirström Karin , Holmquist Mengelbier Linda , Gisselsson David
Published: July 2023

Supplementary Figure 2. Complexity of phylogenetic tree, comparing WT DA to IR and BT WT.
Supplementary Table S5 from TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer
Authors: Heiduk Max , Klimova Anna , Reiche Charlotte , Digomann David , Beer Carolin , Aust Daniela E. , Distler Marius , Weitz Jürgen , Seifert Adrian M. , Seifert Lena
Published: July 2023

Proportion of PD-1+ or TIGIT+ cells of CD8+ T cells, Tconv or Treg ± standard deviation in PDAC according to clinicopathological parameters. Statistics (Stat.) with unpaired two-sided t-test or one-way ANOVA, respectively. *, P < 0.05; **, P < 0.01
Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Authors: Bui Nam Q. , Nemat-Gorgani Neda , Subramanian Ajay , Torres Ileana A. , Lohman Marta , Sears Timothy J. , van de Rijn Matt , Charville Gregory W. , Becker Hans-Christoph , Wang David S. , Hwang Gloria L. , Ganjoo Kristen N. , Moding Everett J.
Published: July 2023

Supplementary Tables S1-S5
Supplementary Figure S6 from TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer
Authors: Heiduk Max , Klimova Anna , Reiche Charlotte , Digomann David , Beer Carolin , Aust Daniela E. , Distler Marius , Weitz Jürgen , Seifert Adrian M. , Seifert Lena
Published: July 2023

Cytokine expression in blood and matched PDAC.
Supplementary Figure S13 from TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer
Authors: Heiduk Max , Klimova Anna , Reiche Charlotte , Digomann David , Beer Carolin , Aust Daniela E. , Distler Marius , Weitz Jürgen , Seifert Adrian M. , Seifert Lena
Published: July 2023

. Illustration depicting T cell subsets that enable dichotomization of PDAC patients with significantly different survival functions.
Supplementary Figure S12 from TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer
Authors: Heiduk Max , Klimova Anna , Reiche Charlotte , Digomann David , Beer Carolin , Aust Daniela E. , Distler Marius , Weitz Jürgen , Seifert Adrian M. , Seifert Lena
Published: July 2023

Survival analyses for PD-1 and TIGIT co-expression in PDAC.
Supplementary Table S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
Authors: Shagisultanova Elena , Gradishar William , Brown-Glaberman Ursa , Chalasani Pavani , Brenner Andrew J. , Stopeck Alison , Parris Hannah , Gao Dexiang , McSpadden Tessa , Mayordomo Jose , Diamond Jennifer R. , Kabos Peter , Borges Virginia F.
Published: July 2023

Characteristics of CNS cohort
Supplementary Table S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
Authors: Shagisultanova Elena , Gradishar William , Brown-Glaberman Ursa , Chalasani Pavani , Brenner Andrew J. , Stopeck Alison , Parris Hannah , Gao Dexiang , McSpadden Tessa , Mayordomo Jose , Diamond Jennifer R. , Kabos Peter , Borges Virginia F.
Published: July 2023

Representativeness of the study participants
Supplementary Fig. S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
Authors: Shagisultanova Elena , Gradishar William , Brown-Glaberman Ursa , Chalasani Pavani , Brenner Andrew J. , Stopeck Alison , Parris Hannah , Gao Dexiang , McSpadden Tessa , Mayordomo Jose , Diamond Jennifer R. , Kabos Peter , Borges Virginia F.
Published: July 2023

Grade 3 and 4 AEs - palbociclib 125mg vs 75mg
Supplementary Table S1 from Patient-Reported Outcomes as Interradiographic Predictors of Response in Non–Small Cell Lung Cancer
Authors: Bhatt Ambika S. , Schabath Matthew B. , Hoogland Aasha I. , Jim Heather S.L. , Brady-Nicholls Renee
Published: July 2023

Patient demographics table
Supplemental Fig. 2 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Authors: Choudhury Noura J. , Lavery Jessica A. , Brown Samantha , de Bruijn Ino , Jee Justin , Tran Thinh Ngoc , Rizvi Hira , Arbour Kathryn C. , Whiting Karissa , Shen Ronglai , Hellmann Matthew , Bedard Philippe L. , Yu Celeste , Leighl Natasha , LeNoue-Newton Michele , Micheel Christine , Warner Jeremy L. , Ginsberg Michelle S. , Plodkowski Andrew , Girshman Jeffrey , Sawan Peter , Pillai Shirin , Sweeney Shawn M. , Kehl Kenneth L. , Panageas Katherine S. , Schultz Nikolaus , Schrag Deborah , Riely Gregory J.
Published: July 2023

Supplemental Figure 2: OS and PFS for patients with NSCLC treated with first-line platinum-based chemotherapy.
Supplemental Fig. 1 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Authors: Choudhury Noura J. , Lavery Jessica A. , Brown Samantha , de Bruijn Ino , Jee Justin , Tran Thinh Ngoc , Rizvi Hira , Arbour Kathryn C. , Whiting Karissa , Shen Ronglai , Hellmann Matthew , Bedard Philippe L. , Yu Celeste , Leighl Natasha , LeNoue-Newton Michele , Micheel Christine , Warner Jeremy L. , Ginsberg Michelle S. , Plodkowski Andrew , Girshman Jeffrey , Sawan Peter , Pillai Shirin , Sweeney Shawn M. , Kehl Kenneth L. , Panageas Katherine S. , Schultz Nikolaus , Schrag Deborah , Riely Gregory J.
Published: July 2023

Supplemental Figure 1: OS and PFS for KRAS-mutated NSCLC treated with first-line platinum-based chemotherapy.
Data from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
Authors: Morgan Robert D. , Clamp Andrew R. , White Daniel J. , Price Marcus , Burghel George J. , Ryder W. David J. , Mahmood Reem D. , Murphy Alexander D. , Hasan Jurjees , Mitchell Claire L. , Salih Zena , Wheeler Chelsey , Buckley Emma , Truelove Joanna , King Georgia , Ainaoui Yasmina , Bhaskar Sanjeev S. , Shaw Joseph , Evans D. Gareth R. , Kilerci Bedirhan , Pearce Simon P. , Brady Gerard , Dive Caroline , O'Connor James P.B. , Wallace Andrew J. , Rothwell Dominic G. , Edmondson Richard J. , Jayson Gordon C.
Published: July 2023

AbstractPurpose:
A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline BRCA1/2-mutant high-grade serous ovarian cancer (gBRCAm-HGSOC). The feasibility of a second maintenance course of PARPi was unknown.
Patients and Methods:
Phase II trial with two entry points (EP1, EP2). Patients were recruited prior to rechallenge platinum. Patients with relapsed, gBRCAm-HGSOC were enrolled at EP1 if they were PARPi-naïve. Patients enrolled at EP2 had received their first course of olaparib prior to trial entry. EP1 patients were retreated with olaparib after RECIST complete/partial response (CR/PR) to platinum. EP2 patients were retreated with olaparib ± cediranib after RECIST CR/PR/stable disease to platinum and according to the platinum-free interval. Co-primary outcomes were the proportion of patients who received a second course of olaparib and the proportion who received olaparib retreatment for ≥6 months. Functional homologous recombination deficiency (HRD), somatic copy-number alteration (SCNA), and BRCAm reversions were investigated in tumor and liquid biopsies.
Results:
Twenty-seven patients were treated (EP1 = 17, EP2 = 10), and 19 were evaluable. Twelve patients (63%) received a second course of olaparib and 4 received olaparib retreatment for ≥6 months. Common grade ≥2 adverse events during olaparib retreatment were anemia, nausea, and fatigue. No cases of MDS/AML occurred. Mean duration of olaparib treatment and retreatment differed (12.1 months vs. 4.4 months; P < 0.001). Functional HRD and SCNA did not predict PFS. A BRCA2 reversion mutation was detected in a post-olaparib liquid biopsy.
Conclusions:
A second course of olaparib can be safely administered to women with gBRCAm-HGSOC but is only modestly efficacious.

See related commentary by Gonzalez-Ochoa and Oza, p. 2563
Data from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Authors: Hwang Justin , Shi Xiaolei , Elliott Andrew , Arnoff Taylor E. , McGrath Julie , Xiu Joanne , Walker Phillip , Bergom Hannah E. , Day Abderrahman , Ahmed Shihab , Tape Sydney , Makovec Allison , Ali Atef , Shaker Rami M. , Toye Eamon , Passow Rachel , Lozada John R. , Wang Jinhua , Lou Emil , Mouw Kent W. , Carneiro Benedito A. , Heath Elisabeth I. , McKay Rana R. , Korn W. Michael , Nabhan Chadi , Ryan Charles J. , Antonarakis Emmanuel S.
Published: July 2023

AbstractPurpose:
In patients with metastatic prostate cancer (mPC), ATM and BRCA2 mutations dictate differences in PARPi inhibitor response and other therapies. We interrogated the molecular features of ATM- and BRCA2-mutated mPC to explain the divergent clinical outcomes and inform future treatment decisions.
Experimental Design:
We examined a novel set of 1,187 mPCs after excluding microsatellite-instable (MSI) tumors. We stratified these based on ATM (n = 88) or BRCA2 (n = 98) mutations. As control groups, mPCs with mutations in 12 other homologous recombination repair (HRR) genes were considered non-BRCA2/ATM HRR-deficient (HRDother, n = 193), whereas lack of any HRR mutations were considered HRR-proficient (HRP; n = 808). Gene expression analyses were performed using Limma. Real-world overall survival was determined from insurance claims data.
Results:
In noncastrate mPCs, only BRCA2-mutated mPCs exhibited worse clinical outcomes to AR-targeted therapies. In castrate mPCs, both ATM and BRCA2 mutations exhibited worse clinical outcomes to AR-targeted therapies. ATM-mutated mPCs had reduced TP53 mutations and harbored coamplification of 11q13 genes, including CCND1 and genes in the FGF family. BRCA2-mutated tumors showed elevated genomic loss-of-heterozygosity scores and were often tumor mutational burden high. BRCA2-mutated mPCs had upregulation of cell-cycle genes and were enriched in cell-cycle signaling programs. This was distinct from ATM-mutated tumors.
Conclusions:
Tumoral ATM and BRCA2 mutations are associated with differential clinical outcomes when patients are stratified by treatments, including hormonal or taxane therapies. ATM- and BRCA2-mutated tumors exhibited differences in co-occurring molecular features. These unique molecular features may inform therapeutic decisions and development of novel therapies.
Data from TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer
Authors: Heiduk Max , Klimova Anna , Reiche Charlotte , Digomann David , Beer Carolin , Aust Daniela E. , Distler Marius , Weitz Jürgen , Seifert Adrian M. , Seifert Lena
Published: July 2023

AbstractPurpose:
Immunotherapy has led to a fundamental shift in the treatment of several cancers. However, its efficacy in pancreatic ductal adenocarcinoma (PDAC) is limited. Understanding the expression of inhibitory immune checkpoint receptors (ICR) by intratumoral T cells may help to unravel their involvement in insufficient T-cell–mediated antitumor immunity.
Experimental Design:
Using multicolor flow cytometry, we analyzed circulating and intratumoral T cells from blood (n = 144) and matched tumor samples (n = 107) of patients with PDAC. We determined the expression of programmed cell death protein 1 (PD-1) and T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibition motif (ITIM) domains (TIGIT) by CD8+ T-cells, conventional CD4+ T-cells (Tconv) and regulatory T cells (Treg) and their association with T-cell differentiation, tumor reactivity, and cytokine expression. A comprehensive follow-up was used to determine their prognostic value.
Results:
Intratumoral T cells were characterized by increased PD-1 and TIGIT expression. Both markers delineated distinct T-cell subpopulations. PD-1+TIGIT− T cells highly expressed proinflammatory cytokines and markers of tumor reactivity (CD39, CD103), whereas TIGIT expression was linked to antiinflammatory and exhausted phenotypes. In addition, the enhanced presence of intratumoral PD-1+TIGIT− Tconv was associated with improved clinical outcomes, while high ICR expression on blood T cells was a significant hazard for overall survival (OS).
Conclusions:
Our results uncover the association between ICR expression and T-cell functionality. PD-1 and TIGIT characterized intratumoral T cells with highly divergent phenotypes linked to clinical outcomes, further underscoring the relevance of TIGIT for immunotherapeutic approaches in PDAC. The prognostic value of ICR expression in patient blood may be a valuable tool for patient stratification.
Data from Efficacy and quality-of-life following involved nodal radiotherapy for head and neck squamous cell carcinoma: the INRT-AIR phase II clinical trial
Authors: Sher David J. , Moon Dominic H. , Vo Dat , Wang Jing , Chen Liyuan , Dohopolski Michael , Hughes Randall , Sumer Baran D. , Ahn Chul , Avkshtol Vladimir
Published: July 2023

Abstract
Purpose: Elective neck irradiation (ENI) has long been considered mandatory when treating head and neck squamous cell carcinoma (HNSCC) with definitive radiotherapy, but it is associated with significant dose to normal organs-at-risk (OAR). In this prospective phase II study, we investigated the efficacy and tolerability of eliminating ENI and strictly treating involved and suspicious lymph nodes (LN) with intensity-modulated radiation therapy. Patients and Methods: Patients with newly-diagnosed HNSCC of the oropharynx, larynx and hypopharynx were eligible for enrollment. Each LN was characterized as involved or suspicious based on radiologic criteria and an in-house artificial intelligence-based classification model. Gross disease received 70 Gray (Gy) in 35 fractions and suspicious LN were treated to 66.5 Gy, without ENI. The primary endpoint was solitary elective volume recurrence, with secondary endpoints including patterns-of-failure and patient-reported outcomes. Results: Sixty-seven patients were enrolled, with 18 larynx/hypopharynx and 49 oropharynx cancer. With a median follow-up of 33.4 months, the 2-year risk of solitary elective nodal recurrence was 0%. Gastrostomy tubes were placed in 14 (21%), with median removal after 2.9 months for disease-free patients; no disease-free patient is chronically dependent. Grade 1/2 dermatitis was seen in 90%/10%. There was no significant decline in composite MD Anderson Dysphagia Index (MDADI) scores after treatment, with means of 89.1 and 92.6 at 12 and 24 months, respectively. Conclusions: These results suggest that eliminating ENI is oncologically sound for HNSCC, with highly favorable quality-of-life outcomes. Additional prospective studies are needed to support this promising paradigm before implementation in any non-trial setting.
Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
Authors: Boyle Eileen M. , Blaney Patrick , Stoeckle James H. , Wang Yubao , Ghamlouch Hussein , Gagler Dylan , Braunstein Marc , Williams Louis , Tenenbaum Avital , Siegel Ariel , Chen Xiaoyi , Varma Gaurav , Avigan Jason , Li Alexander , Jinsi Monica , Kaminetzsky David , Arbini Arnaldo , Montes Lydia , Corre Jill , Rustad Even H. , Landgren Ola , Maura Francesco , Walker Brian A. , Bauer Michael , Bruno Benedetto , Tsirigos Aristotelis , Davies Faith E. , Morgan Gareth J.
Published: July 2023

Purpose:

Chromosome 1 (chr1) copy-number abnormalities (CNA) and structural variants (SV) are frequent in newly diagnosed multiple myeloma (NDMM) and are associated with a heterogeneous impact on outcomes, the drivers of which are largely unknown.

Experimental Design:

A multiomic approach comprising CRISPR, gene mapping of CNAs and SVs, methylation, expression, and mutational analysis was used to document the extent of chr1 molecular variants and their impact on pathway utilization.

Results:

We identified two distinct groups of gain(1q): focal gains associated with limited gene-expression changes and a neutral prognosis, and whole-arm gains, which are associated with substantial gene-expression changes, complex genetics, and an adverse prognosis. CRISPR identified a number of dependencies on chr1 but only limited variants associated with acquired CNAs. We identified seven regions of deletion, nine of gain, three of chromothripsis (CT), and two of templated insertion (TI), which contain a number of potential drivers. An additional mechanism involving hypomethylation of genes at 1q may contribute to the aberrant gene expression of a number of genes. Expression changes associated with whole-arm gains were substantial and gene set enrichment analysis identified metabolic processes, apoptotic resistance, signaling via the MAPK pathway, and upregulation of transcription factors as being key drivers of the adverse prognosis associated with these variants.

Conclusions:

Multiple layers of genetic complexity impact the phenotype associated with CNAs on chr1 to generate its associated clinical phenotype. Whole-arm gains of 1q are the critically important prognostic group that deregulate multiple pathways, which may offer therapeutic vulnerabilities.
Supplementary Figure 5 from Major histocompatibility complex-class II is induced by Interferon-gamma and follows three distinct patterns of expression in colorectal cancer organoids
Authors: Pickles Oliver J , Wanigasooriya Kasun , Ptasinska Anetta , Patel Akshay J. , Robbins Helen L , Bryer Claire , Whalley Celina M , Tee Louise , Lal Neeraj , Pinna Maria , Elzefzafy Nahla , Taniere Philippe , Beggs Andrew D , Middleton Gary M.
Published: July 2023

The four weakly-inducible organoids were treated with a range of concentration of GSK126 between 0-10 µM for 72 hours, prior to determining the cell viability using CellTiter-Glo 3D Cell Viability Assay. Results were scaled relative to untreated control cells (given relative viability of 1.0) and all conditions were based on a minimum of five replicates. Mean values with standard deviation displayed. Small increases in viability noted in 3 out of 4 lines with low doses up to 2 µM, consistent with prior literature.
Supplementary Figure 4 from Major histocompatibility complex-class II is induced by Interferon-gamma and follows three distinct patterns of expression in colorectal cancer organoids
Authors: Pickles Oliver J , Wanigasooriya Kasun , Ptasinska Anetta , Patel Akshay J. , Robbins Helen L , Bryer Claire , Whalley Celina M , Tee Louise , Lal Neeraj , Pinna Maria , Elzefzafy Nahla , Taniere Philippe , Beggs Andrew D , Middleton Gary M.
Published: July 2023

Non-inducible organoids demonstrate no further upregulation of Class II following IFNγ cotreatment with Azacitidine. The three non-inducible organoids (376, 557 and 946) were treated with control or 72 hours IFNγ 75 IU/ml +/- 6 days 2 µM Azacitidine. Flow cytometry assessment of Class II upregulation from representative experiments displayed.
Chemoprävention: Nicotinamid schützt Transplantatempfänger*innen nicht vor neuen epithelialen Hauttumoren
Authors: Schilling Bastian
Published: July 2023

Immunsupprimierte Organtransplantatempfänger haben eine erhöhte Inzidenz von Hautkrebs und sterben häufiger daran. Nicotinamid (Vitamin B3) verbessert die Reparatur von durch ultraviolette (UV) Strahlung verursachten DNA-Schäden, reduziert die immunsuppressive Wirkung von UV-Strahlung auf die Haut und verringert die Inzidenz von Keratinozytenkrebs (einschließlich Plattenepithelkarzinom und Basalzellkarzinom) und aktinischen Keratosen bei immunkompetenten Patienten mit hohem Risiko. Ob orales Nicotinamid zur chemopräventiven Behandlung von Hautkrebs bei Organtransplantatempfängern nützlich ist, ist unklar. In dieser Phase-3-Studie wurden Organtransplantatempfänger, die in den letzten 5 Jahren mindestens zwei Krebsfälle hatten, im Verhältnis 1:1 randomisiert, um 12 Monate lang zweimal täglich 500 mg Nicotinamid oder Placebo einzunehmen. Der primäre Endpunkt war die Anzahl neuer Tumoren während des 12-monatigen Interventionszeitraums. Sekundäre Endpunkte waren die Anzahl von Plattenepithel- und Basalzellkarzinomen während des 12-monatigen Interventionszeitraums, die Anzahl von aktinischen Keratosen bis 6 Monate nach der Randomisierung, die Sicherheit und die Lebensqualität. Die Studie wurde aufgrund schlechter Rekrutierung vorzeitig abgebrochen. Es wurden keine signifikanten Unterschiede zwischen den Gruppen in Bezug auf die Anzahl von Plattenepithel- und Basalzellkarzinomen, aktinischen Keratosen oder Lebensqualitätsscores beobachtet. Nebenwirkungen und Veränderungen der Blut- oder Urinlaborwerte waren in beiden Gruppen ähnlich.
Optimizing performance parameters of stationary wire free power transfer circuit
Authors: Vidya Raja , Keshavan Belur K.
Published: July 2023

The power efficiency of the wire free power transmission (WPT) system is tested in this article under various transmission distance circumstances, and the findings are utilized to investigate the best way to regulate the parameters for charging electric vehicles (EVs). The system`s power transfer efficiency is improved over using a fixed resonant frequency by altering it in response to changes in the coupling coefficient. In relation to resonance frequency, a trade-off between output power magnitude and power efficiency is also revealed. Through numerical simulation with Ansys, the trade-off resonant frequencies at various transmission lengths are determined by the analysis. Here, the transmitter and receiver employ circular coils with a circular cross-sectional area and a straightforward but effective series-series (SS) compensation architecture is used for comprehensive analysis.
Optimal AGC of a power system incorporated BESS-EHVAC/DC link using evolutionary techniques
Authors: Kumar Ashwini , Singh Omveer
Published: July 2023

This research paper reveals the design of controller with optimization techniques for automatic generation control (AGC) in multi-area power system incorporated with diverse energy sources. The diverse sources are conventional thermal, hydro and gas power station (THG). The frequency deviations should be remains constant in modern power systems. Optimization techniques used for proposed model for proportional integral (PI) controller which is tuned for AGC with diverse energy sources. The battery energy storage system (BESS) and extra high voltage alternating current/ direct current (EHVAC/DC) link investigated with proposed model.  The proposed model has been tested with 1% step load perturbation (SLP) and MATLAB/Simulink verified their results. All the simulation results justified the area control error (ACE) with frequency deviation & tie-line power flow for area-1 and area-2. The comparative study done for PI controller with GA & PSO in the proposed model. It has shown its efficacy with proposed model including BESS and EHVAC/DC- link using GA and PSO.
Development of a method for regenerative braking of an electric scooter
Authors: Serykhanovna Bigaliyeva Zhanar , Utebayev Ruslan , Baktybayev Murat , Temirzhanov Alisher , Kunelbayev Murat Merkebekovich
Published: July 2023

In this work, a method of regenerative braking of an electric scooter was developed. Regenerative braking of electric vehicles is the basis for energy saving cars and environmental protection. A stand was made for the study of a magnets and an ionistor. In the proposed method, an ionistor is additionally connected in parallel to the battery, which charges faster than the battery, so the process of accelerating the electric vehicle after stopping also occurs faster. It should also be noted that if emergency braking is necessary to stop an electric vehicle, the driver can press the brake pedal and stop the car using brake pads. The paper investigates the method of the element base for the vehicle, as well as control. To develop this study, an electric scooter was chosen as an electric vehicle model. The dependences of the electric current on the operating time of the ionistor in three positions are determined. During the actual speed of the electric scooter corresponds to the controlled speed.
Dynamic programming-based control system development for advanced electric power drive
Authors: Wadkar Swapnil Ramesh , Patil Sudhir Madhav , Dhanvijay Maneetkumar R. , Chaudhari Kiran Ashokrao , Karanjkar Atul Vasant
Published: July 2023

An efficient method for raising the effectiveness and performance of fuel cell electric vehicles (FCEVs) is the dynamic programming controller (DPC). By using real-time data to optimize the control inputs, FCEVs can achieve higher levels of efficiency and reduce their environmental impact. The DPC algorithm works by solving an optimization problem at each time step, based on the current state of the vehicle and its environment. The optimal control inputs are then applied to the vehicle to achieve the desired performance criteria. This paper presents the study that utilized MATLAB/Simulink to design, model, and simulate DPC for a FCEV. Controlling various components of the fuel cell (FC) with the optimum power requirement is needed for increasing the performance and mileage of the FCEV. It's important to use FC energy as effectively as possible. Having supervisory control over the FCEV's energy consumption and battery charging is necessary for it to produce this output at its best. To use the hydrogen efficiently, a control strategy is designed for energy management in FCEV. The designed control strategies are implemented through simulation using Simulink in MATLAB. The results show prominent performance of dynamic programming (DP) over rule-based controllers.
Fault tolerant control for DFIG wind turbine controlled by ADRC and optimized by genetic algorithm
Authors: Aissaoui Ikram , Elmouhi Noureddine , Essadki Ahmed , Elaimani Hind
Published: July 2023

This research work deals with the modelling, control and simulation of a wind turbine based on the doubly fed induction generator (DFIG) in the current sensor’s failure event. We present in the first time the model of the wind energy conversion system based on the DFIG and the control by active disturbances rejection control (ADRC) optimized by genetic algorithm. Particular focus is directed towards on a technique for detection, identification, isolation and reconfiguration of current sensor signals after failure. The combination of the two preceding techniques makes it possible to have a fault tolerant control to sensor faults which ensures continuity of service in all circumstances. The robustness of the proposed technique is tested under the MATLAB/Simulink environment.
Semi-automatic of steer by wire system using fuzzy logic control and swarm optimization
Authors: Hunaini Fachrudin , Nafis Dicky Dikananda , Suwandono Purbo , Subiyakto Gatot
Published: July 2023

The semi-automatic steer by wire system is a vehicle steering system that does not use a mechanical link but uses an electric drive, so that the steer wheel is equipped with an angle sensor as a control system input to adjust the electric drive rotation when determining the direction of the front wheels of the vehicle. The control system uses fuzzy logic control (FLC) is optimized using swarm-based optimization. Performance testing of the optimal control system is carried out using Software in the loop simulations and hardware in the loop simulations which were then applied to the steering system prototype equipped with rack-pinion and wheel steer. The test results show that the optimal control system performance reaches a C-RMS error of 6.712. The prototype that was built has two kinds of ratios between the steering angle and the vehicle wheel angle, namely a ratio of 1:6.25 for speeds below 10 km/h making it suitable for operation when the vehicle is maneuvering in the parking area and a ratio of 1:25 for speeds above 10 km/h which is suitable for operation when the vehicle is traveling at medium or high speed.
Investigation on various stator structure towards noise and vibration
Authors: Abdullah Nurfaezah , Karim Kasrul Abdul , Othman Raja Nor Firdaus Raja , Jidin Auzani , Sutikno Tole
Published: July 2023

This research analyses the noise and vibration characteristics of permanent magnet motors (PMM) with the electromagnetic characteristics, with an emphasis on high-speed motor segmented closed slot stator. The interaction between the stator, rotor, and magnets can cause a vibration that results in the loud sound due to the high magnetic energy. Even if there aren't many vibrations to contend with, the fluctuation of motor vibrations causes more serious harm. The studies covered slotted stator, closed slot stator, and segmented with closed slot stator. The objective is to analyze the cogging torque relation towards vibration and the effect of natural frequency at steady-state behavior of the structure. ANSYS finite element analysis (FEA) is used to generate electromagnetic analysis performance whilst ANSYS mechanical used to simulate the modal and harmonic analysis at the stator tooth tips surface to define the structure when the steady-state condition under vibrational stimulation. Anticipation on this work shows, the lowest cogging torque produce less radiated sound. Thus, the result indicates the cogging torque profiles had good agreement with the equivalent radiated power level (ERPL) waterfall diagram.